Meda enters into joint venture with Valeant

Meda enters into joint venture with Valeant

Meda and Valeant Pharmaceuticals International have agreed to form joint
ventures in Australia, Canada and Mexico to develop, market and commercialize
certain current and future products. The joint ventures will be majority owned
by Meda and Valeant will own a minority interest. The joint ventures will pursue
the regulatory filings and manage the commercialization of the products and
Valeant will participate in a profit share. The joint ventures will initially
include products such as Sublinox (treatment of insomnia) and flupertine (pain
treatment), with the option to include additional products in the future.

“We are very pleased to be able to join Valeant in the creation of these three
joint ventures,” said Ander Lonner, chief executive officer of Meda. “Long-term
partnerships are a fundamental cornerstone of Meda's strategy and I believe that
this collaboration will yield long-term benefits for both companies.”

“I am delighted to join Meda in a strategic partnership that will provide new
opportunities for both companies,” stated J. Michael Pearson, chairman and chief
executive officer of Valeant. “Through these joint ventures, Valeant will be
able to increase the leverage of our business
operations in Canada, Mexico and Australia, while opening up new market
opportunities for
Meda.“

For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 8 630 19 62, +46
709 458 878
email: anders.larnholt@meda.se



MEDA AB (publ) is an international specialty pharma company that concentrates on
marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda is
represented with own organisations in 26 countries and with more than 1 500
employees within marketing and sales. Meda's products are sold in approximately
120 countries world-wide. The Meda share is listed under Large Cap on the OMX
Nordic Stock Exchange. Find out more, visit www.meda.se.  

Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a broad range of
products primarily in the areas of neurology and dermatology. More information
about Valeant can be found at www.valeant.com.